Combination Immunotherapy in Pancreatic Cancer: Current Clinical Evidence and Mechanistic Rationale for Overcoming a “Cold” Tumor

Abstract

Simple Summary Pancreatic cancer usually responds poorly to drugs that release the brakes on immune cells. Combining these drugs with other treatments may help, but early responses do not show which treatment contributed or whether patients live longer. This review examines clinical studies alongside four interacting problems: inadequate recognition of cancer, restricted access by immune cells, suppression by surrounding cells, and impaired immune function. These groups help organize questions for research; they are not a validated method of choosing treatment. We distinguish randomized comparisons from uncontrolled signals and immune changes from clinical benefit. Important limitations include selected patient groups, different treatment backbones, incomplete sampling, and uncertainty in some of the published results. Rare molecular features can identify patients eligible for established immunotherapy, but the benefit of adding another treatment remains uncertain. Future studies should test specific treatment contributions, measure the relevant biology when feasible, and assess symptoms, daily function, toxicity, and quality of life.